BioPharma Dive July 1, 2024
Study results are expected for a pair of closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.
In early May, executives at Amgen gave a rosy review of their experimental drug for obesity, telling investors they were confident the medicine could soon move into late-stage testing. The bullish comments were enough to swell the company’s market value, already among the industry’s largest, by nearly $20 billion.
They also revealed the degree to which new treatments for weight loss are reshaping the pharmaceutical sector. Already, the success of Wegovy and Zepbound...
Today's Sponsors
Today's Sponsor